BCL2L11 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 769-P human renal epithelial carcinoma cell line, carrying a targeted disruption of the BCL2L11 gene. This loss-of-function model enables the systematic investigation of BCL2L11 (BIM) function in apoptosis regulation within a renal cell carcinoma background.
The 769-P cell line is an established human clear cell renal cell carcinoma (ccRCC) model isolated from a primary tumor. These adherent, epithelial-like cells retain key features of malignant kidney epithelium and are widely employed in renal cancer research, including studies of oncogenic signaling, drug resistance, and tumor cell survival mechanisms.
BCL2L11 encodes BIM, a BH3-only pro-apoptotic protein central to the intrinsic apoptotic pathway. BIM sequesters anti-apoptotic BCL-2 family members such as BCL-2, BCL-xL, and MCL-1, thereby liberating BAX and BAK to form pores in the mitochondrial outer membrane, triggering cytochrome c release and subsequent assembly of the apoptosome with Apaf-1 and caspase-9, culminating in effector caspase activation. BIM activity is tightly regulated by multiple upstream signals: transcriptional induction by FOXO transcription factors downstream of PI3K/AKT inhibition, and post-translational control through ERK-mediated phosphorylation that targets BIM for ubiquitin-dependent degradation, and JNK-mediated phosphorylation that can enhance pro-apoptotic function. Cytokine withdrawal and glucocorticoid treatment also upregulate BIM, linking growth factor signaling to cell death commitment.
In the context of 769-P ccRCC cells, disruption of BCL2L11 attenuates the intrinsic apoptotic response, making this polyclonal knockout population a critical tool for dissecting apoptosis resistance mechanisms frequently observed in renal cell carcinoma. Because standard therapies often induce cell death via BIM-dependent pathways, this model facilitates the study of acquired resistance to targeted agents and BH3-mimetic drugs. Moreover, it permits the analysis of cross-talk between MAPK/ERK and PI3K/AKT survival signaling and the apoptotic machinery, revealing how oncogenic kinases suppress BIM to promote tumor cell survival.
BCL2L11 Knockout 769-P Polyclonal Cells support a range of experimental applications, including apoptosis mechanism studies, drug-induced cell death assays, and BH3-mimetic drug testing. Researchers can compare wild-type and BIM-deficient populations using western blotting for caspase activation, Annexin V staining for phosphatidylserine exposure, mitochondrial membrane potential flow cytometry, and BH3 profiling to assess reliance on specific BCL-2 family dependencies. Additionally, co-immunoprecipitation can probe altered BCL-2 family interactomes, while cell viability assays under various stress conditions reveal BIM’s role in therapy response. This product is ideal for investigating resistance mechanisms to targeted therapies in renal cancer and for validating the apoptotic efficacy of investigational compounds. For additional technical details, please contact Ascent Research.
